Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel, Gemcitabine and Bevacizumab as Salvage Therapy for Metastatic Breast Cancer

NCT00754351 is registered in ClinicalTrials.gov with University Hospital of Crete as lead sponsor.

NCT NCT00754351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00754351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel, Gemcitabine and Bevacizumab as Salvage Therapy for Metastatic Breast Cancer
Lead sponsor
University Hospital of Crete
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2008
Completion date
February 29, 2012
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer